Business
NurExone Announces Corporate Updates
Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement ClosingTORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced several developments supporting its planned growth, increasing awareness in Europe, and
About this update from Bayer Ag
[{"type":"image","alt":"NurExone Biologic Inc","displaySize":"","headline":null,"caption":"NurExone Biologic Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/c6e879a2d8f96b03c7effe65222bd22d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4Hpu5iIb3xN7ditW8ptX6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c6e879a2d8f96b03c7effe65222bd22d","width":300,"height":70}},"lazy":false},{"type":"text","content":"Consulting Agreement with Former Bayer Principal Scientist, BOLD Awards Healthcare Finalist Status, and Private Placement Closing","length":129,"tagName":"p"},{"type":"text","content":"TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced several developments supporting its planned growth, increasing awareness in Europe, and the closing of a private placement.","length":406,"tagName":"p"},{"type":"text","content":"Consulting Agreement with Former Bayer Scientist","length":48,"tagName":"p"},{"type":"text","content":"The Company has signed a consulting agreement with Dr. Lars Bärfacker, an experienced medicinal chemist and former Principal Research Scientist at Bayer AG, to support aspects of NurExone’s European scientific and strategic initiatives. Dr. Bärfacker has more than two decades of experience in drug discovery and innovation and has contributed to the discovery of several clinical compounds, including Finerenone (Kerendia®), now approved for the treatment of cardiorenal diseases.","length":481,"tagName":"p"},{"type":"text","content":"NurExone CEO, Dr. Lior Shaltiel, noted: “Lars brings many years of experience in the exosome field and a deep understanding of extracellular vesicle biology and its potential therapeutic applications, including his experience at Bayer. His perspective will be valuable as NurExone continues advancing its regenerative medicine platform globally, particularly in Europe.”","length":370,"tagName":"p"},{"type":"text","content":"Finalist at the BOLD Awards","length":27,"tagName":"p"},{"type":"text","content":"NurExone has also been named a finalist in ...